Peanut Allergy Treatment Market Size, Share & Trends Analysis Report By Drug Class (Antihistamines, Epinephrine, Immunotherapies), By Route Of Administration, By Distribution Channel, By Region, And Segment Forecasts, 2023 To 2030

Peanut allergy is witnessing a rise in prevalence burden in the last decade. According to Food Allergy Research & Education, about 32 million general population suffer from disease in the U.S., of which 6.1 million patients are allergic to peanuts. Along with increasing prevalence, the rising investment of key public and private organizations in developing novel drugs to treat patients augment the demand for treatment and drive the market.

Furthermore, key players are using various strategies to enhance their pipeline for peanut allergies. For instance, in December 2022, Aravax initiated its series B round with an investment of USD 20 million from Brandon Capital and Tenmile, leading Australian life science investors. This funding will support Aravax to start a phase 2 clinical trial of PVX108 in patients with peanut allergy. Such investments are expected to propel R&D programs.

The allergies are often experienced at a young age when the immune system is underdeveloped. Some children grow out of condition, but many children experience signs and symptoms throughout their lifetime. According to the Asthma and Allergy Foundation of America, nearly 2% of the total children population in the U.S. have a peanut allergy. The medicines most commonly used for treatment include antihistamines (Claritin), epinephrine (AUVI-Q, EpiPen, Symjepi, and Adrenaclick), immunotherapies (Odactra, Palforzia), and others. Furthermore, oral immunotherapeutic drugs have demonstrated successful results in affected patients reducing symptoms associated with peanut allergy globally.

Several key players are launching novel drugs to address the growing prevalence of disease. For instance, in January 2020, the U.S. FDA approved Aimmune Therapeutic’s Palforzia, indicated for the management of signs & symptoms associated with this disease. Furthermore, in October 2022, Allergy partners collaborated with Aimmune Therapeutics to provide Palforzia powder to patients for treatment. This approval is expected to support the global commercialization and expansion of treatment.

However, adverse reactions associated with drug use, high cost associated with treatment, and lack of awareness about disease in developing countries is expected to restrain market growth over the forecast period.

Peanut Allergy Treatment Market Segmentation

Major companies operating in the market include Sanofi, Aimmune Therapeutics, DBV Technologies, Vedanta Biosciences, Inc., Alladapt Immunotherapeutics, Inc., Regeneron Pharmaceuticals Inc., Aravax Pty Ltd, Teva Pharmaceutical Industries Limited, and Prota Therapeutics among others.